Evidence map›Paper›PMID 39817285›Full record

ArticlePhysics and imaging in radiation oncology2025

Normal tissue complication probability model for severe radiation-induced lymphopenia in patients with pancreatic cancer treated with concurrent chemoradiotherapy.

Fuki Koizumi, Norio Katoh, Takahiro Kanehira, Yasuyuki Kawamoto, Toru Nakamura, Tatsuhiko Kakisaka, Miyako Myojin, Noriaki Nishiyama, Akio Yonesaka, Manami Otsuka and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Physics and imaging in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Fuki KoizumiDepartment of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.
Norio KatohDepartment of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.
Takahiro KanehiraDepartment of Medical Physics, Hokkaido University Hospital, North 14 West 5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan.
Yasuyuki KawamotoDivision of Cancer Center, Hokkaido University Hospital, North 14 West 5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan.
Toru NakamuraDepartment of Gastroenterological Surgery Ⅱ, Hokkaido University Faculty of Medicine, North 15 West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.
Tatsuhiko KakisakaDepartment of Gastroenterological Surgery Ⅰ, Hokkaido University Hospital, North 14 West 5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan.
Miyako MyojinDepartment of Radiation Oncology, Keiyukai Sapporo Hospital, South 1-1, Hondori-9, Shiroishi-ku, Sapporo, Hokkaido 003-0026, Japan.
Noriaki NishiyamaDepartment of Radiation Oncology, Hokkaido Cancer Center, 2-3-54, Kikusui-4, Shiroishi-ku, Sapporo, Hokkaido 003-0804, Japan.
Akio YonesakaDepartment of Radiology, Kushiro Rosai Hospital, 13-23, Nakazonocho, Kushiro, Hokkaido 085-8533, Japan.
Manami OtsukaDepartment of Radiation Oncology, Hokkaido Cancer Center, 2-3-54, Kikusui-4, Shiroishi-ku, Sapporo, Hokkaido 003-0804, Japan.
Rikiya TakashinaDepartment of Radiation Oncology, Hokkaido Cancer Center, 2-3-54, Kikusui-4, Shiroishi-ku, Sapporo, Hokkaido 003-0804, Japan.
Hideki MinatogawaDepartment of Radiation Oncology, Hokkaido Cancer Center, 2-3-54, Kikusui-4, Shiroishi-ku, Sapporo, Hokkaido 003-0804, Japan.
Hajime HigakiDepartment of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.
Yusuke UchinamiDepartment of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.
Hiroshi TaguchiDepartment of Radiation Oncology, Hokkaido University Hospital, North 14 West 5, Kita-ku, Sapporo 060-8648, Japan.
Kentaro NishiokaGlobal Center for Biomedical Science and Engineering, Hokkaido University Faculty of Medicine, North 15 West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.
Koichi YasudaDepartment of Radiation Oncology, Hokkaido University Hospital, North 14 West 5, Kita-ku, Sapporo 060-8648, Japan.
Naoki MiyamotoDepartment of Medical Physics, Hokkaido University Hospital, North 14 West 5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan.
Isao YokotaDepartment of Biostatistics, Hokkaido University Faculty of Medicine, North 15 West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.
Keiji KobashiGlobal Center for Biomedical Science and Engineering, Hokkaido University Faculty of Medicine, North 15 West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.
Hidefumi AoyamaDepartment of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Radiation-induced lymphopenia (RIL) may be associated with a worse prognosis in pancreatic cancer. This study aimed to develop a normal tissue complication probability (NTCP) model to predict severe RIL in patients with pancreatic cancer undergoing concurrent chemoradiotherapy (CCRT). Materials and methods: We reviewed pancreatic cancer patients treated at our facility for model training and internal validation. Subsequently, we reviewed data from three other facilities to validate model fit externally. An absolute lymphocyte count (ALC) of ＜0.5 × 10 Results: Among the 114 patients in the training set, 78 had severe RIL. LASSO showed that low baseline ALC, large planning target volume, and high percentage of bilateral kidneys receiving ≥ 5Gy were selected as parameters of the NTCP model for severe RIL. The AUC and scaled Brier score were 0.91 and 0.49, respectively. Internal validation yielded an average AUC of 0.92. In the external validation with 68 patients, the AUC and scaled Brier score was 0.83 and 0.30, respectively. Calibration plots showed good conformity. Conclusions: The NTCP model for severe RIL during CCRT for pancreatic cancer, developed and validated in this study, demonstrated good predictive performance. This model can be used to evaluate and compare the risk of RIL.

Indexed as

Absolute lymphocyte countConcurrent chemoradiotherapyKidney doseNormal tissue complication probability modelPancreatic cancerRadiation-induced lymphopenia

Identifiers

PMID39817285
PMCPMC11733268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.